Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Appointment of Dr. Spicer to Scientific Advisory Board bolsters expertise in Neutrophil Extracellular Traps ("NETs") in cancer biology and provides valuable assistance in advancing development of the Company's DNase platform FRAMINGHAM, MA / ACCESSWIRE / November 16, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of Jonathan Spicer, MD, PhD to its Scientific Advisory Board ("SAB"). Dr. Spicer is recognized as a leader in understanding how neutrophils impact cancer progression, in particular, the role of NETs in cancer biology, and has developed one of the most active research programs in the area of neoadjuvant immunotherapy for operable lung cancer.

Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform

- Continued advancement of lead technology, DNase-based oncology platform, in locally advanced or metastatic solid tumors towards Phase 1 clinical development - Ended the quarter with $13.8 million of cash expected to fund operations and drive expanded pipeline development forward FRAMINGHAM, MA / ACCESSWIRE / November 10, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today reported its financial results for the third quarter of 2022 and provided a business update. "We have continued to make encouraging progress with our recently in-licensed DNase-based oncology asset over the course of the past quarter and are excited about the potential of this platform technology," commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.

Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Volitionrx Limited

Signing of patent assignment from CLS Therapeutics as part of a collaboration agreement with Volition and CLS Therapeutics to develop NETs-targeted adoptive cell therapies for the treatment of cancer FRAMINGHAM, MA / ACCESSWIRE / October 11, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced the signing of a patent assignment from CLS Therapeutics, Inc. ("CLS") to Xenetic related to Xenetic's previously announced collaboration with VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, and CLS, a biopharmaceutical company developing first-in-class therapies based on the discovery of novel therapeutic targets. In consideration of the patent assignment, Xenetic will also issue 850,000 shares of common stock to CLS.

Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics

FRAMINGHAM, MA / ACCESSWIRE / October 4, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the appointment of Allan Tsung, MD to its Scientific Advisory Board. Dr. Tsung is a nationally and internationally recognized leader specializing in evaluating and caring for patients with liver, bile duct and pancreas cancers and is an expert in laparoscopic and robotic surgery.

Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board

FRAMINGHAM, MA / ACCESSWIRE / September 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the H.C.

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Second quarter marked by deal to in-license DNase-based oncology platform which expands pipeline with well-defined and accelerated path to clinic Advancing lead DNase program towards Phase 1 study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the quarter with $14.9 million of cash to fund operations and drive expanded pipeline development forward FRAMINGHAM, MA / ACCESSWIRE / August 12, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today reported its financial results for the second quarter of 2022 and provided a business update. "The past quarter was marked by a shift in our focus and prioritization of our pipeline with the in-licensing of our DNase-based oncology platform.

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Inc

VolitionRx (NYSE-A:VNRX) Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to treat cancer and help advance a drug designed to treat solid and hematologic cancers. First off, the company will collaborate with Xenetic Biosciences (NASDAQ:XBIO) Inc to evaluate the potential combination of Volition's Nu.Q NETs Test and Xenetic's DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers.

VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences and Salarius Pharmaceuticals in push to develop cancer treatments

FRAMINGHAM, MA / ACCESSWIRE / August 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, and VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, today announced a research and development collaboration to develop Neutrophil Extracellular Traps ("NETs") targeted, adoptive cell therapies for the treatment of cancer. The collaboration is an early exploratory program to evaluate the potential combination of Volition's Nu.Q® NETs Test and Xenetic's DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers.

Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

DNase-based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indications Systemic DNase program initially targeting multi-billion-dollar indications including pancreatic carcinoma FRAMINGHAM, MA / ACCESSWIRE / July 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, today announced it has entered into a manufacturing agreement with Catalent Pharma Solutions LLC ("Catalent"), which will include cGMP manufacturing for the Company's recombinant protein, Human DNase I. Catalent is the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities.

Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study

- Live video webcast with moderated roundtable with members of the Xenetic leadership team and surgical oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET - FRENCHTOWN, NJ / ACCESSWIRE / June 2, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor Innovation in Oncology Event Featuring Xenetic Biosciences on Thursday, June 9, 2022 at 11:00 AM ET. Access the event here.

JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences

Live Video Webcast With Moderated Roundtable With Members of the Xenetic Leadership Team and Surgical Oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / June 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that it will participate in the Virtual Investor Innovation in Oncology Event on Thursday, June 9, 2022 at 11:00 AM ET. For the roundtable discussion, Jeffrey F.

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event

Live Webcast Presentation on Wednesday, May 25th at 4:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 18, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic, will present at the H.C.

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference

- Company completed recent transaction to expand oncology pipeline with in-licensing of DNase based platform comprising multiple therapeutic modalities - DNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indications - Focusing resources on advancing DNase based oncology platform in locally advanced or metastatic solid tumors towards Phase 1 clinical development - Ended the quarter with $16.2 million of cash to fund operations and drive pipeline forward FRAMINGHAM, MA / ACCESSWIRE / May 12, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today reported its financial results for the first quarter of 2022 and provided a business update. "Our strategic focus throughout the first quarter was working towards the completion of our exclusive license agreement with CLS Therapeutics ("CLS") to develop its interventional DNase based oncology platform.

Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical development opportunity DNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indications Xenetic plans to conduct a Phase 1 clinical study of lead asset in locally advanced or metastatic solid tumors Company to host update conference call and webcast today, April 27th at 8:30 AM ET FRAMINGHAM, MA / ACCESSWIRE / April 27, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that it has entered into exclusive license and sublicense agreements with CLS Therapeutics ("CLS") to develop its interventional DNase based oncology platform, which is aimed at improving outcomes of existing treatments, including immunotherapies. Xenetic will host a conference call and webcast, today, April 27, 2022, at 8:30 a.m.

Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities

- XCARTTM continuing to advance toward IND-enabling studies - PolyXen® platform technology growing royalty stream through license agreement - Closed the year with $18.2 million of cash FRAMINGHAM, MA / ACCESSWIRE / March 23, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial results for the full year 2021 and provided a corporate update. "Over the course of the past year, our team has continued to advance the XCART program through pre-clinical studies, which are key to defining the best development pathway for this novel platform technology.

Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update

Company advancing XCARTTM pre-clinical development plan toward IND-enabling studies Strengthened cash position to fund operations through XCART IND filing with recently completed $12.5 million private placement Continued royalty stream growth through license agreement with PolyXen® platform technology FRAMINGHAM, MA / ACCESSWIRE / November 12, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial results for the third quarter of 2021 and provided a corporate update. "Our team continues to advance the XCART program and validate key workflow and manufacturing components which move us closer to conducting IND-enabling studies.

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

Xenetic Biosciences (XBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Xenetic Biosciences (XBIO) to Report a Decline in Earnings: What to Look Out for

Allowance bolsters intellectual property portfolio for differentiated personalized CAR T platform technology, XCART FRAMINGHAM, MA / ACCESSWIRE / September 9, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced the United States Patent and Trademark Office (USPTO) has issued Xenetic a Notice of Allowance for U.S. patent application number 16/983,491 entitled, "Articles and Methods Directed to Personalized Therapy of Cancer," covering the co-administration of XCART-derived CAR T cells together with a personalized vaccine designed to enhance the effectiveness of the CAR T therapy. "We believe our XCART platform technology has the potential to offer cancer patients substantial benefits over the existing standard of care and currently approved CAR T therapies.

Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent

FRAMINGHAM, MA / ACCESSWIRE / September 8, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the virtual H.C.

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Kadmon Hlds

Safe Bulkers

Senseonics Holdings

Verb Technology Company Inc

Penny stocks to buy according to analysts with price targets up to 300% right now. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 300% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks Analysts Say To Buy With Targets Up To 300%

Continued execution on XCART TM pre-clinical development plan and progress toward IND-enabling studies  Strong royalty growth with PolyXen® platform technology  Bolstered cash position with recently completed $12.5 million private placement  FRAMINGHAM, MA / ACCESSWIRE / August 13, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial results for the second quarter of 2021 and provided a corporate update. "Over the course of the second quarter, we continued to execute our innovative and differentiated XCART program, and the technical progress we've accomplished brings us closer to the critical milestone of conducting IND-enabling studies in the United States.

Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

The shares of Xenetic Biosciences Inc (NASDAQ: XBIO) increased by over 37% during intraday trading. This is why it happened.

Xenetic Biosciences Shares Increase Over 37% Intraday: Why It Happened

The stock price of Xenetic Biosciences Inc (NASDAQ: XBIO) increased by 65.11% yesterday. This is why it happened.

XBIO Stock Increased 65.11%: Details You Should Know

FRAMINGHAM, MA / ACCESSWIRE / July 28, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced the closing of its previously announced private placement with a single healthcare-focused institutional investor for 4,629,630 shares of its common stock (or common stock equivalents) at a purchase price per share of $2.70, priced at-the-market under Nasdaq rules. The gross proceeds to Xenetic totaled approximately $12.5 million before deducting placement agent fees and other offering expenses.

Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market

XBIO stock is continuing a heck of a week. Just days after it was boosted by Takeda's expansion news, it's looking at a big private sale.

News for Xenetic Biosciences Stock (XBIO)